Simvastatin Reduces Adiponectin Levels and Insulin Sensitivity

This study has been completed.

Sponsored by:	Gachon University Gil Medical Center
Information provided by:	Gachon University Gil Medical Center
ClinicalTrials.gov Identifier:	NCT00546182

Purpose

We hypothesized simvastatin may reduce adiponectin levels and insulin sensitivity in overweight hypercholesterolemic patients.

Condition
Hypercholesterolemia

Genetics Home Reference related topics: hypercholesterolemia

MedlinePlus related topics: Cholesterol

Drug Information available for: Insulin Simvastatin

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case Control, Prospective
Official Title:	Phase 4 Study of Simvastatin That Affects Insulin Sensitivity

Further study details as provided by Gachon University Gil Medical Center:

Primary Outcome Measures:

simvastatin may reduce adiponectin levels and insulin sensitivity in overweight hypercholesterolemic patients

Biospecimen Retention: Samples Without DNA

Biospecimen Description:

Study Start Date:

January 2004

Eligibility

Ages Eligible for Study:	25 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Study Population

overweight hypercholesterolemic patients

Criteria

Inclusion Criteria:

Low-density lipoprotein cholesterol levels more than 100 and body mass index more than 23.0

Exclusion Criteria:

Patients with overt liver disease
Chronic renal failure
Hypothyroidism, myopathy
Uncontrolled diabetes
Severe hypertension, stroke
Acute coronary events
Coronary revascularization within the preceding 3 months, or
Alcohol abuse.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00546182

Locations

Korea, Republic of
Gil Medical Center, Gachon University
Incheon, Korea, Republic of, 405760

Sponsors and Collaborators

Gachon University Gil Medical Center

Investigators

Principal Investigator:

Kwang K Koh, MD,PhD

Gachon University Gil Medical Center

More Information

Publications of Results:

Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol. 1999 Mar;126(5):1205-13.

Study ID Numbers:	GMC-200405
Study First Received:	October 17, 2007
Last Updated:	October 17, 2007
ClinicalTrials.gov Identifier:	NCT00546182
Health Authority:	Institutional Review Board: Republic of Korea

Keywords provided by Gachon University Gil Medical Center:

Lipophilic statins
Insulin resistance
hypercholesterolemic patients

Study placed in the following topic categories:

Metabolic Diseases
Hyperlipidemias
Simvastatin
Insulin Resistance
Metabolic disorder

Hypercholesterolemia
Insulin
Dyslipidemias
Lipid Metabolism Disorders

Additional relevant MeSH terms:

Antimetabolites
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Antilipemic Agents

Enzyme Inhibitors
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009